HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jegerlehner, A. Articles by Bachmann, M. F. Search for Related Content PubMed PubMed Citation Articles by Jegerlehner, A. Articles by Bachmann, M. F.

Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity

Andrea Jegerlehner^*, Nicole Schmitz, Tazio Storni^* and Martin F. Bachmann^1,*

^* Cytos Biotechnology, Schlieren, Switzerland; and Molecular Biomedicine, Department of Environmental Sciences, Swiss Federal Institute of Technology Zurich, Zurich-Schlieren, Switzerland

Vaccination of mice with a peptide corresponding to the extracellular part of M2 protein coupled to the immunodominant domain of hepatitis B core can protect mice from a lethal challenge with influenza A virus. As the extracellular part of M2 protein is highly conserved in all known human influenza A strains, such a vaccine may protect against all human influenza A strains, which would represent a major advantage over current vaccine strategies. The present study demonstrates that protection is mediated exclusively by Abs, a very important feature of a successful preventive vaccine. However, these Abs neither bind efficiently to the free virus nor neutralize virus infection, but bind to M2 protein expressed on the surface of virus-infected cells. The presence of NK cells is important for protection, whereas complement is not, supposing that protection is mediated via Ab-dependent, cell-mediated cytotoxicity. The absence of neutralizing Abs results in much weaker protection than that achieved by vaccination with UV-inactivated influenza virus. Specifically, whereas neutralizing Abs completely eliminate signs of disease even at high viral challenge doses, M2-specific Abs cannot prevent infection, but merely reduce disease at low challenge doses. M2-specific Abs fail to protect from high challenge doses, as vaccinated mice undergo lethal infection under these conditions. In conclusion, protection mediated by M2-hepatitis B core vaccine would be insufficient during the yearly epidemics, for which full protection is desirable, and overall is clearly inferior to protection achieved by immunization with classical inactivated viral preparations.

This article has been cited by other articles:

				J. Gabbard, N. Velappan, R. Di Niro, J. Schmidt, C.A. Jones, S.M. Tompkins, and A.R.M. Bradbury A humanized anti-M2 scFv shows protective in vitro activity against influenza Protein Eng. Des. Sel., March 1, 2009; 22(3): 189 - 198. [Abstract] [Full Text] [PDF]

				E. Bianchi, X. Liang, P. Ingallinella, M. Finotto, M. A. Chastain, J. Fan, T.-M. Fu, H. C. Song, M. S. Horton, D. C. Freed, et al. Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor J. Virol., June 15, 2005; 79(12): 7380 - 7388. [Abstract] [Full Text] [PDF]

				D. Zharikova, K. Mozdzanowska, J. Feng, M. Zhang, and W. Gerhard Influenza Type A Virus Escape Mutants Emerge In Vivo in the Presence of Antibodies to the Ectodomain of Matrix Protein 2 J. Virol., June 1, 2005; 79(11): 6644 - 6654. [Abstract] [Full Text] [PDF]